Teva Pharma Q3 Beats Market, Lifts FY24 Outlook
Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Wednesday reported a loss in its third quarter, compared to prior year's profit, despite higher revenues. However, adjusted earnings and top line beat market estimates, and the firm lifted its fiscal 2024 forecast.
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today ...
JERUSALEM (Reuters) - Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in ...
UBS walked away from meetings with Teva (TEVA) management confident that the firm’s bullish thesis with a Street-high price target of $26 ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...
Teva Pharmaceutical Industries Ltd. (TEVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the ...
EPS, expectations were $0.66. Operator: Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings ...
QRG Capital Management Inc. cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 1.6% during the third quarter, according to the company in its most recent ...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new patient- and physician-reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback